Chuck Royce acquired 207 Thousand Halozyme Therapeutics shares worth $13.6 Million. That's 0.15% of their equity portfolio (200th largest holding). The first Halozyme Therapeutics trade was made in Q1 2013. Since then Chuck Royce bought shares seven more times and sold shares on eight occasions. The stake costed the investor $8.66 Million, netting the investor a gain of 57% so far.